<SEC-DOCUMENT>0001171843-20-001588.txt : 20200310
<SEC-HEADER>0001171843-20-001588.hdr.sgml : 20200310
<ACCEPTANCE-DATETIME>20200310073012
ACCESSION NUMBER:		0001171843-20-001588
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20200310
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200310
DATE AS OF CHANGE:		20200310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XOMA Corp
		CENTRAL INDEX KEY:			0000791908
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				522154066
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-14710
		FILM NUMBER:		20699918

	BUSINESS ADDRESS:	
		STREET 1:		2200 POWELL STREET
		STREET 2:		SUITE 310
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
		BUSINESS PHONE:		510-204-7239

	MAIL ADDRESS:	
		STREET 1:		2200 POWELL STREET
		STREET 2:		SUITE 310
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XOMA LTD /DE/
		DATE OF NAME CHANGE:	19990107

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XOMA CORP /DE/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k_030920.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html><head><title></title></head><body><div style="margin-top: 3pt; margin-bottom: 12pt;"><div style="font-size: 1pt; border-top: Black 2.5pt solid; border-bottom: Black 1.1pt solid; width: 100%;"><font style="font-size: 10pt;">&#160;</font></div></div><p style="text-align: center;"><font style="font-size: 14pt;"><strong>UNITED STATES</strong><br /><strong>SECURITIES AND EXCHANGE COMMISSION</strong><br /><strong>Washington, D.C. 20549</strong><br />_____________________</font></p><p style="text-transform: uppercase; text-align: center;"><font style="font-size: 14pt;"><strong>Form 8-K</strong><br />_____________________</font></p><p style="text-align: center;"><font style="font-size: 12pt;"><strong>CURRENT REPORT</strong></font></p><p style="text-align: center;"><font style="font-size: 12pt;"><strong>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</strong></font></p><p align="center"><font style="font-size: 10pt;">Date of Report (Date of earliest event Reported): <!--March 10, 2020-->March 10, 2020 &#160;</font></p><p align="center"><font style="font-size: 12pt;"><strong>XOMA CORPORATION</strong></font><br /><font style="font-size: 10pt;">(Exact Name of Registrant as Specified in Charter)</font></p><table style="width: 100%;" border="0" cellspacing="0" cellpadding="0"><tr valign="top"><td align="center" width="33%"><font style="font-size: 10pt;"><strong>DELAWARE</strong></font></td><td align="center" width="34%"><font style="font-size: 10pt;"><strong>000-14710</strong></font></td><td align="center" width="33%"><font style="font-size: 10pt;"><strong>52-2154066</strong></font></td></tr><tr valign="top"><td align="center" width="33%"><font style="font-size: 10pt;">(State or Other Jurisdiction of Incorporation)</font></td><td align="center" width="34%"><font style="font-size: 10pt;">(Commission File Number)</font></td><td align="center" width="33%"><font style="font-size: 10pt;">(I.R.S. Employer Identification Number)</font></td></tr></table><p><font style="font-size: 10pt;">&#160;</font></p><table style="width: 100%;" border="0" cellspacing="0" cellpadding="0"><tr valign="bottom"><td align="center" width="50%"><font style="font-size: 10pt;"><strong>2200 Powell Street, Suite 310, Emeryville, California 94608</strong><!----></font></td></tr><tr valign="top"><td align="center" width="50%"><font style="font-size: 10pt;">(Address of Principal Executive Offices) (Zip Code)</font></td></tr></table><p align="center"><font style="font-size: 10pt;"><strong>(510) 204-7200</strong><br />(Registrant's telephone number, including area code)</font></p><p align="center"><font style="font-size: 10pt;"><strong></strong><br />(Former name or former address, if changed since last report)</font></p><p style="box-sizing: inherit; font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 4.54%; margin-top: 0pt; margin-bottom: 0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="box-sizing: inherit; font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 4.54%; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p><table style="box-sizing: inherit; border-spacing: 0px; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; width: 1047px; height: 35px;" border="0" cellspacing="0" cellpadding="0" align="center"><tr style="box-sizing: inherit; vertical-align: top;"><td style="box-sizing: inherit; padding: 0px; text-align: center; text-indent: 0pt; width: 687.5px;">Title of each class:</td><td style="box-sizing: inherit; padding: 0px; text-align: center; text-indent: 0pt; width: 588.75px;">Trading symbol(s):</td><td style="box-sizing: inherit; padding: 0px; text-align: center; text-indent: 0pt; width: 686.25px;">Name of each exchange on which registered:</td></tr><tr style="box-sizing: inherit; vertical-align: top;"><td style="box-sizing: inherit; padding: 0px; text-align: center; text-indent: 0pt;">Common Stock, $0.0075 par value</td><td style="box-sizing: inherit; padding: 0px; text-align: center; text-indent: 0pt;">XOMA</td><td style="box-sizing: inherit; padding: 0px; text-align: center; text-indent: 0pt;">The Nasdaq Global Market</td></tr></table><table style="width: 100%;" border="0" cellspacing="0" cellpadding="0"><tr valign="top"><td colspan="3"><font style="font-size: 10pt;"><br />Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:<br /><br /></font></td></tr><tr valign="top"><td width="21"><font style="font-size: 10pt;">&#160;</font></td><td width="40"><font style="font-size: 10pt;">[ &#160; ]</font></td><td nowrap="nowrap"><font style="font-size: 10pt;">&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></td></tr><tr valign="top"><td width="21"><font style="font-size: 10pt;">&#160;</font></td><td width="40"><font style="font-size: 10pt;">[ &#160; ]</font></td><td nowrap="nowrap"><font style="font-size: 10pt;">&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td></tr><tr valign="top"><td width="21"><font style="font-size: 10pt;">&#160;</font></td><td width="40"><font style="font-size: 10pt;">[ &#160; ]</font></td><td nowrap="nowrap"><font style="font-size: 10pt;">&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></td></tr><tr valign="top"><td width="21"><font style="font-size: 10pt;">&#160;</font></td><td width="40"><font style="font-size: 10pt;">[ &#160; ]</font></td><td nowrap="nowrap"><font style="font-size: 10pt;">&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></td></tr></table><p style="font-size: 10pt; margin: 0pt;">&#160;</p><p style="font-size: 10pt; margin: 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule&#160;12b-2&#160;of the Securities Exchange Act of 1934 (17 CFR&#160;&#167;240.12b-2).&#160;Emerging growth company [&#160;&#160; ]</p><p style="font-size: 10pt; margin: 0pt;">&#160;</p><p style="font-size: 10pt; margin: 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [&#160;&#160; ]</p><div style="margin-top: 12pt; margin-bottom: 3pt;"><div style="font-size: 1pt; border-top: Black 1.1pt solid; border-bottom: Black 2.5pt solid; width: 100%;"><font style="font-size: 10pt;">&#160;</font></div>&#160;</div><hr style="page-break-after: always;" noshade="noshade" /><p><font style="font-size: 10pt;">  <strong>  </strong></font></p><p><font style="font-size: 10pt;"><strong>Item 2.02. Results of Operations and Financial Condition.</strong></font></p><p><font style="font-size: 10pt;">
 <p>On March 10, 2020, XOMA Corporation issued a press release announcing its financial results for the quarter ended December 31, 2019. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</p>  <p>The information in this Form 8-K and the Exhibit attached hereto shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</p> </font></p><p><font style="font-size: 10pt;"><strong>  </strong></font></p><p><font style="font-size: 10pt;"><strong>Item 9.01. Financial Statements and Exhibits.</strong></font></p><p><font style="font-size: 10pt;">
 <p>(d) Exhibits</p> <table style="width:815; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td style="vertical-align: bottom ; "><font style="font-size:10pt;"><strong><u>Number</u></strong></font></td><td class="hugin"><font style="font-size:10pt;">&#160;</font></td><td style="vertical-align: bottom ; "><font style="font-size:10pt;"><strong><u>Description of Document</u></strong></font></td></tr><tr><td class="hugin">&#160;</td><td class="hugin"><font style="font-size:10pt;">&#160;</font></td><td class="hugin"><font style="font-size:10pt;">&#160;</font></td></tr><tr><td class="hugin"><font style="font-size:10pt;"><font style="font-size:10pt;"><a href="exh_991.htm" rel="nofollow">99.1</a></font></font></td><td class="hugin"><font style="font-size:10pt;">&#160;</font></td><td class="hugin"><font style="font-size:10pt;"><font style="font-size:10pt;"><a href="exh_991.htm" rel="nofollow">Press release entitled "XOMA Reports Fourth Quarter and Full-Year 2019 Financial Results and Operating Highlights" dated March 10, 2020</a></font></font></td></tr></table></font></p><p><font style="font-size: 10pt;"></font></p><p><font style="font-size: 10pt;"></font></p><hr style="page-break-after: always;" noshade="noshade" /><p align="center"><font style="font-size: 10pt;"><strong>SIGNATURE</strong></font></p><p><font style="font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p><table style="width: 100%;" border="0" cellspacing="0" cellpadding="0"><tr valign="top"><td valign="top" width="49%"><font style="font-size: 10pt;">&#160;</font></td><td style="font-size: 12pt;" colspan="2" valign="top"><font style="font-size: 10pt;"><strong>XOMA CORPORATION</strong></font></td></tr><tr valign="top"><td width="49%"><font style="font-size: 10pt;">&#160;</font></td><td width="2%"><font style="font-size: 10pt;">&#160;</font></td><td width="49%"><font style="font-size: 10pt;">&#160;</font></td></tr><tr valign="top"><td width="49%"><font style="font-size: 10pt;">&#160;</font></td><td width="2%"><font style="font-size: 10pt;">&#160;</font></td><td width="49%"><font style="font-size: 10pt;"></font></td></tr><tr valign="top"><td width="49%"><font style="font-size: 10pt;">Date: March 10, 2020</font></td><td width="2%"><font style="font-size: 10pt;">By:&#160;</font></td><td style="text-decoration: underline;" width="49%"><font style="font-size: 10pt;">/s/ THOMAS BURNS&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></td></tr><tr valign="top"><td width="49%"><font style="font-size: 10pt;">&#160;</font></td><td width="2%"><font style="font-size: 10pt;">&#160;</font></td><td width="49%"><font style="font-size: 10pt;">Thomas Burns</font></td></tr><tr valign="top"><td width="49%"><font style="font-size: 10pt;">&#160;</font></td><td width="2%"><font style="font-size: 10pt;">&#160;</font></td><td width="49%"><font style="font-size: 10pt;">Senior Vice President, Finance and Chief Financial Officer</font></td></tr><tr valign="top"><td width="49%"><font style="font-size: 10pt;">&#160;</font></td><td width="2%"><font style="font-size: 10pt;">&#160;</font></td><td width="49%"><font style="font-size: 10pt;"></font></td></tr></table><p /></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"><html lang="en-US"><head><title>EdgarFiling</title><meta content="text/html; charset=windows-1252" ><meta name="GENERATOR" content="MSHTML 8.00.7601.18094" ></head><body bgcolor="#ffffff"><p style="text-align: right;"><strong>EXHIBIT 99.1</strong></p><p style="text-align: center;"><font style="font-size: 14pt;"><strong>XOMA Reports Fourth Quarter and Full-Year 2019 Financial Results and Operating Highlights</strong></font></p><p style="text-align: center;"><strong></strong></p><p>
   <p align="center"><em>Added more than 20 new partner-funded programs in 2019 with potential for milestone and royalty payments&#160;<br ></em><em>Received $15.8 million from partners during the year&#160;<br ></em><em>Current cash balance sufficient to fund operations for multiple years</em></p>    <p>EMERYVILLE, Calif., March  10, 2020  (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) announced its fourth quarter and full-year 2019 financial results and business highlights.</p>    <p>&#8220;2019 was a tremendous year for XOMA.&#160; We added 20 new assets to our royalty license portfolio, eleven of which are clinical-stage candidates.&#160; One of our licensees, Janssen Biotech, conducted a portfolio review and identified multiple compounds that were born from an agreement between our companies.&#160; As we are constructing XOMA&#8217;s portfolio to generate royalty candidates over an extended time horizon, we acquired interests in two exciting platform technologies that we believe will produce multiple clinical candidates to further increase our royalty license portfolio.&#160; We entered 2020 with a royalty-potential portfolio of more than 65 partner-funded assets,&#8221; stated Jim Neal, Chief Executive Officer at XOMA.&#160; &#8220;Our business model has the potential to generate significant revenue from milestone payments and royalties.&#160; In 2019, we received $15.8 million from our partners.&#160; Given our royalty acquisition achievements over the last three years and the opportunities before us, we raised an additional $22 million in a rights offering at the end of the year.&#160; We anticipate we will deploy this capital to continue building XOMA&#8217;s royalty-interest and milestone-bearing portfolio.&#8221;&#160;</p>    <p><strong>Business Highlights</strong><br >XOMA completed four milestone and royalty acquisition transactions in 2019 that added eleven new potential royalty-bearing assets and interests in two platform technologies to the Company&#8217;s portfolio.&#160;</p>    <ul type="disc"><li>Acquired a milestone and royalty interest in two Bayer assets, one Bayer option, and two unpartnered candidates from Aronora.</li><li>Acquired a royalty interest in one Novartis asset and five clinical-stage assets from Palobiofarma.</li><li>Acquired royalty interest in platform technologies being developed at Bioasis Technologies and Sonnet BioTherapeutics.</li><li>Added nine Janssen Biotech assets to XOMA&#8217;s royalty portfolio.</li><li>Received $15.8 million from partners during 2019.</li><li>Completed a $22 million rights offering with XOMA stockholders including BVF Partners, LP.</li></ul>    <p><strong>2019 Updates About Partnered Assets in Development</strong><br >&#8220;Last year two of our partners, Novartis and Sesen Bio, announced significant clinical developments that have the potential to offer patients with few treatment options the opportunity to access new therapies that have clinically meaningful benefits,&#8221; Mr. Neal continued.</p>    <p>Novartis-licensed assets:</p>    <ul type="disc"><li>Novartis presented first-of-its-kind histology data with iscalimab (CFZ533)<sup>1</sup> at the American Transplant Congress. &#160;The data showed 60 percent of iscalimab-treated transplant patients have normal kidney histology at least one year after transplant, compared with 0 percent with tacrolimus (current standard of care)<sup>2</sup>. &#160;The company highlighted iscalimab and its development plans at the Novartis R&amp;D Day on December 5, 2019. &#160;Novartis now has seven clinical studies with iscalimab underway.</li><li>Novartis launched its clinical program for gevokizumab (VPM087) (anti-IL1&#946; allosteric modulator monoclonal antibody)<sup> 3</sup> with a clinical study in patients with metastatic colorectal cancer, gastroesophageal cancer, and renal cell carcinoma.</li></ul>    <p>Sesen Bio reported positive top-line Phase 3 data and subsequently initiated its rolling Biologics License Application (BLA) filing for Vicinium<sup>&#174;</sup> for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)<sup>4</sup>.&#160; The company has stated it anticipates completing its filing in the second half of 2020.</p>    <p>Takeda-licensed assets:</p>    <ul type="disc"><li>Takeda expanded the TAK-079<sup>4</sup> clinical program and now has four studies ongoing.</li><li>Takeda and Molecular Templates began enrolling patients in their first TAK-169<sup>4</sup> clinical program.</li></ul>    <p>Aronora initiated a Phase 2 study with AB002 (E-WE thrombin)<sup>4</sup> in patients with end-stage renal disease on chronic hemodialysis.</p>    <p>AVEO Oncology expanded the clinical program testing ficlatuzumab (AV-299)<sup>4</sup> and now is studying the compound&#8217;s potential efficacy in a wide variety of oncology indications.&#160;</p>    <p>Mr. Neal concluded, &#8220;The clinical advancements continued into 2020.&#160; In February, Rezolute, Inc., announced the launch of its Phase 2b clinical trial for RZ358 (formerly XOMA 358) in patients with congenital hyperinsulinism (CHI).&#160; Given the insight we gained into this terrible condition during our early development of this compound and the extraordinary families we met, we are truly hopeful Rezolute succeeds in its development efforts for RZ358.&#8221;</p>    <p><strong>Financial Results</strong><br >XOMA recorded total revenues of $0.4 million for the fourth quarter of 2019, compared to $1.7 million for the fourth quarter of 2018.&#160; For the full year of 2019, XOMA recorded revenues of $18.4 million, compared to $5.3 million for the full year of 2018.&#160; Revenues for the full year of 2019 reflect $14.0 million recognized under the Company&#8217;s license agreement and common stock purchase agreement with Rezolute and $2.5 million in revenue earned from a one-time payment under XOMA&#8217;s license agreement with Janssen.&#160; Revenues for the full year of 2018 include $1.8 million recognized under the license agreement and common stock purchase agreement with Rezolute, $1.4 million in milestone revenue earned under XOMA&#8217;s license agreement with Janssen, and $0.8 million in milestone revenue earned under XOMA&#8217;s license agreement with Compugen.<em>&#160; </em></p>    <p>Research and development (R&amp;D) expenses were $0.1 million for the fourth quarter of 2019, compared to $0.2 million for the fourth quarter of 2018.&#160; Research &amp; development expenses for the full year of 2019 were $1.3 million, compared to $1.7 million for the same period in 2018. &#160;The decrease of $0.4 million in 2019, as compared with 2018, was primarily due to a reduction in headcount of R&amp;D employees.</p>    <p>General and administrative expenses were $4.3 million for the fourth quarter of 2019, compared to $4.3 million for the fourth quarter of 2018.&#160; General &amp; administrative expenses were $21.0 million for the full year of 2019, compared to $18.6 million for the full year of 2018. &#160;The increase of $2.4 million in 2019 as compared with 2018 was primarily due to a $0.9 million increase for expenses incurred in connection with a separation agreement with our Chief Business Officer, which included $0.5 million in stock-based compensation expense for modifications to vested stock options and $0.4 million in separation benefits, an increase of $0.7 million in stock-based compensation excluding the option modifications, a $0.6 million increase in common area maintenance charges related to our legacy leases, and a $0.4 million increase in expenses related to investor communications.</p>    <p>Interest expense for the fourth quarter of 2019 was $0.6 million, as compared to $0.4 million for the fourth quarter of 2018.&#160; For the full year of 2019, interest expense was $1.9 million, compared with $0.9 million reported in the full year of 2018.&#160; The increase in 2019 is primarily due to the increase in the outstanding loan balance with Silicon Valley Bank due to the Company&#8217;s borrowing activities related to the royalty purchase agreements with Aronora and Palobiofarma.</p>    <p>Other income, net was $0.3 million for the fourth quarter of 2019, compared to $0.7 million for the corresponding quarter of 2018.&#160; Total other income, net was $3.8 million for the full year of 2019, compared to $4.3 million for the corresponding period of 2018.&#160; The decrease in the full year of 2019 when compared to the full year of 2018 primarily reflects the discontinuation of income under the Ology Bioservices agreement of $2.5 million and a loss of $0.4 million recognized due to the early termination of our legacy building leases, partially offset by the increase in sublease income of $1.2 million and the change in fair value adjustment of Rezolute common stock of $0.9 million.&#160;&#160;</p>    <p>Net loss for the fourth quarter of 2019 was $4.3 million, compared to net loss of $3.0 million for the fourth quarter of 2018.&#160; Net loss for the full year of 2019 was $2.0 million, compared to net loss of $13.3 million for the full year of 2018.&#160;</p>    <p>On December&#160;31, 2019, XOMA had cash of $56.7 million compared with $45.8 million on December&#160;31, 2018. &#160;The Company&#8217;s current cash position is expected to be sufficient to fund its operations for multiple years.</p>    <p><strong>About XOMA Corporation</strong><br >XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies.&#160; The Company&#8217;s portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas.&#160; Many of these licenses are the result of XOMA&#8217;s pioneering efforts in the discovery and development of antibody therapeutics.&#160; The Company&#8217;s royalty-aggregator business model includes acquiring additional licenses to programs with third-party funding.&#160; For more information, visit <u>www.xoma.com</u>.</p>    <p><strong>Forward-Looking Statements/Explanatory Notes</strong><br >Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the potential of XOMA&#8217;s portfolio of partnered programs and licensed technologies generating substantial milestone and royalty proceeds over time, creating additional value for the stockholders and cash sufficiency forecast.&#160; These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry, including those related to the fact that our product candidates subject to out-license agreements are still being developed, and our licensees may require substantial funds to continue development which may not be available; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; if the therapeutic product candidates to which we have a royalty interest do not receive regulatory approval, our third-party licensees will not be able to market them.&#160; Other potential risks to XOMA meeting these expectations are described in more detail in XOMA's most recent filing on Form 10-K and in other SEC filings.&#160; Consider such risks carefully when considering XOMA's prospects.&#160; Any forward-looking statement in this press release represents XOMA's views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date.&#160; XOMA disclaims any obligation to update any forward- looking statement, except as required by applicable law.</p>    <p>EXPLANATORY NOTE: Any references to &#8220;portfolio&#8221; in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development.&#160; Any references to &#8220;assets&#8221; in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development.&#160;</p>    <ol type="1"><li value="1">Iscalimab is an investigational compound. &#160;Efficacy and safety have not been established. &#160;There is no guarantee that iscalimab will become commercially available.</li><li>Farkash E, et al. Cni-free Therapy With Iscalimab (anti-cd40 Mab) Preserves Allograft Histology Compared To Standard Of Care After Kidney Transplantation. &#160;Iscalimab is an investigational compound. &#160;Efficacy and safety have not been established. &#160;There is no guarantee that iscalimab will become commercially available.&#160; Presented at the American Transplant Congress, June 2019.</li><li>Gevokizumab is an investigational compound. &#160;Efficacy and safety have not been established. &#160;There is no guarantee that gevokizumab will become commercially available.</li><li>This is an investigational compound, and there is no guarantee it will become commercially available.</li></ol>  <table style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td colspan="8" style="text-align: center ;  vertical-align: middle; "><strong>XOMA CORPORATION</strong></td></tr><tr><td colspan="8" style="text-align: center ;  vertical-align: middle; "><strong>CONDENSED CONSOLIDATED BALANCE SHEETS</strong></td></tr><tr><td colspan="8" style="text-align: center ;  vertical-align: middle; "><strong>(unaudited)</strong></td></tr><tr><td colspan="8" style="text-align: center ;  vertical-align: middle; "><strong>(in thousands, except share and per share amounts)</strong></td></tr><tr><td style="text-align: center ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="text-align: center ;  vertical-align: middle; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="text-align: center ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="text-align: center ;  vertical-align: middle; "><strong>December&#160;31,</strong></td><td style="text-align: center ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="text-align: center ;  vertical-align: middle; "><strong>December&#160;31,</strong></td></tr><tr><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2019</strong><br ></td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2018</strong><br ></td></tr><tr><td style="text-align: center ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="text-align: center ;  vertical-align: middle; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="text-align: center ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="text-align: center ;  vertical-align: middle; "><strong>ASSETS</strong></td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td><td class="hugin">&#160;</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="text-align: left ;  vertical-align: middle; ">Current assets:</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td><td class="hugin">&#160;</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="max-width:79%; width:79%; min-width:79%;;vertical-align: middle;   text-align: left;   padding-left: 20.0px; ">Cash</td><td style="max-width:1%; width:1%; min-width:1%;;padding-right: 0 ; text-align: right ;  vertical-align: middle; ">$</td><td style="max-width:8%; width:8%; min-width:8%;;padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">56,688</td><td style="max-width:1%; width:1%; min-width:1%;;padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td class="hugin" style="max-width:1%; width:1%; min-width:1%;">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;padding-right: 0 ; text-align: right ;  vertical-align: middle; ">$</td><td style="max-width:8%; width:8%; min-width:8%;;padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">45,780</td><td style="max-width:1%; width:1%; min-width:1%;;padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 20.0px; ">Trade and other receivables</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">2,933</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td class="hugin">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">1,468</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 20.0px; ">Prepaid expenses and other current assets</td><td style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">352</td><td style="border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td class="hugin">&#160;</td><td style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">378</td><td style="border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 30.0px; ">Total current assets</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">59,973</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td class="hugin">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">47,626</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="text-align: left ;  vertical-align: middle; ">Property and equipment, net</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">34</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td class="hugin">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">59</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="text-align: left ;  vertical-align: middle; ">Operating lease right-of-use assets</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">510</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td class="hugin">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#8212;</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="text-align: left ;  vertical-align: middle; ">Long-term royalty receivables</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">34,375</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td class="hugin">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">15,000</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="text-align: left ;  vertical-align: middle; ">Equity securities</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">681</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td class="hugin">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">392</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="text-align: left ;  vertical-align: middle; ">Other assets</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">151</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td class="hugin">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">708</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 30.0px; ">Total assets</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">$</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">95,724</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td class="hugin">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">$</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">63,785</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 30.0px; ">&#160;</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td><td class="hugin">&#160;</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="text-align: center ;  vertical-align: middle; "><strong>LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</strong></td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="text-align: left ;  vertical-align: middle; ">Current liabilities:</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td><td class="hugin">&#160;</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 20.0px; ">Accounts payable</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">$</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">614</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td class="hugin">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">$</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">1,244</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 20.0px; ">Accrued and other liabilities</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">945</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td class="hugin">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">2,382</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 20.0px; ">Contingent consideration under royalty purchase agreements</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">75</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td class="hugin">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#8212;</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 20.0px; ">Operating lease liabilities</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">163</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td class="hugin">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#8212;</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 20.0px; ">Unearned revenue recognized under units-of-revenue method</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">1,096</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td class="hugin">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">490</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 20.0px; ">Contract liabilities</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">798</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td class="hugin">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">798</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 20.0px; ">Current portion of long-term debt</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">5,184</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td class="hugin">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">789</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 30.0px; ">Total current liabilities</td><td style="border-top: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="border-top: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">8,875</td><td style="border-top: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td class="hugin">&#160;</td><td style="border-top: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="border-top: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">5,703</td><td style="border-top: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="text-align: left ;  vertical-align: middle; ">Unearned revenue recognized under units-of-revenue method &#8211; long-term</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">15,317</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td class="hugin">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">17,017</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="text-align: left ;  vertical-align: middle; ">Long-term debt</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">27,093</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td class="hugin">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">21,690</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="text-align: left ;  vertical-align: middle; ">Long-term operating lease liabilities</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">408</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td class="hugin">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#8212;</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="text-align: left ;  vertical-align: middle; ">Other liabilities &#8211; long-term</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">43</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td class="hugin">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">590</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 30.0px; ">Total liabilities</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">51,736</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td class="hugin">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">45,000</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="text-align: right ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td><td class="hugin">&#160;</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="text-align: left ;  vertical-align: middle; ">Stockholders&#8217; equity:</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td><td class="hugin">&#160;</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 20.0px; ">Convertible preferred stock, $0.05 par value, 1,000,000 shares authorized, 6,256 shares issued and outstanding at December 31, 2019 and December 31, 2018</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#8212;</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td class="hugin">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#8212;</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 20.0px; ">Common stock, $0.0075 par value, 277,333,332 shares authorized, 9,758,583 and 8,690,723 shares issued and outstanding at December 31, 2019 and December 31, 2018, respectively</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">73</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td class="hugin">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">65</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 20.0px; ">Additional paid-in capital</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">1,238,299</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td class="hugin">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">1,211,122</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 20.0px; ">Accumulated deficit</td><td style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">(1,194,384</td><td style="border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">)</td><td class="hugin">&#160;</td><td style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">(1,192,402</td><td style="border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">)</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 30.0px; ">Total stockholders&#8217; equity</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">43,988</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td class="hugin">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">18,785</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 30.0px; ">Total liabilities and stockholders&#8217; equity</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">$</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">95,724</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td class="hugin">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">$</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">63,785</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 30.0px; ">&#160;</td><td colspan="3" style="border-top: solid black 1pt ; text-align: right ;  vertical-align: middle; ">&#160;</td><td class="hugin">&#160;</td><td colspan="3" style="border-top: solid black 1pt ; text-align: right ;  vertical-align: middle; ">&#160;</td></tr></table>  <p><br ></p>  <table style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td colspan="16" style="text-align: center ;  vertical-align: middle; "><strong>XOMA CORPORATION</strong></td></tr><tr><td colspan="16" style="text-align: center ;  vertical-align: middle; "><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</strong></td></tr><tr><td colspan="16" style="text-align: center ;  vertical-align: middle; "><strong>(unaudited)</strong></td></tr><tr><td colspan="16" style="text-align: center ;  vertical-align: middle; "><strong>(in thousands)</strong></td></tr><tr><td class="hugin">&#160;</td><td class="hugin" colspan="3">&#160;</td><td class="hugin">&#160;</td><td class="hugin" colspan="3">&#160;</td><td class="hugin">&#160;</td><td class="hugin" colspan="3">&#160;</td><td class="hugin">&#160;</td><td class="hugin" colspan="3">&#160;</td></tr><tr><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td colspan="7" style="text-align: center ;  vertical-align: middle; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="text-align: left ;  vertical-align: middle; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; ">&#160;</td><td class="hugin" colspan="3">&#160;</td></tr><tr><td style="text-align: right ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td colspan="7" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>Three Months Ended December 31,</strong></td><td style="text-align: center ;  vertical-align: middle; ">&#160;</td><td colspan="7" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>Year Ended December 31,</strong></td></tr><tr><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2019</strong><br ></td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2018</strong><br ></td><td style="text-align: center ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2019</strong><br ></td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2018</strong><br ></td></tr><tr><td style="text-align: left ;  vertical-align: middle; ">Revenues:</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="max-width:57%; width:57%; min-width:57%;;vertical-align: middle;   text-align: left;   padding-left: 10.0px; ">Revenue from contracts with customers</td><td style="max-width:1%; width:1%; min-width:1%;;padding-right: 0 ; text-align: right ;  vertical-align: middle; ">$</td><td style="max-width:8%; width:8%; min-width:8%;;padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">100</td><td style="max-width:1%; width:1%; min-width:1%;;padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;text-align: left ;  vertical-align: middle; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;padding-right: 0 ; text-align: right ;  vertical-align: middle; ">$</td><td style="max-width:8%; width:8%; min-width:8%;;padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">1,550</td><td style="max-width:1%; width:1%; min-width:1%;;padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;text-align: right ;  vertical-align: middle; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;padding-right: 0 ; text-align: right ;  vertical-align: middle; ">$</td><td style="max-width:8%; width:8%; min-width:8%;;padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">17,276</td><td style="max-width:1%; width:1%; min-width:1%;;padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;text-align: left ;  vertical-align: middle; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;padding-right: 0 ; text-align: right ;  vertical-align: middle; ">$</td><td style="max-width:8%; width:8%; min-width:8%;;padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">5,068</td><td style="max-width:1%; width:1%; min-width:1%;;padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 10.0px; ">Revenue recognized under units-of-revenue method</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">323</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">135</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">1,094</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">231</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 20.0px; ">Total revenues</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">423</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">1,685</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">18,370</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">5,299</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 10.0px; ">&#160;</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="text-align: left ;  vertical-align: middle; ">Operating expenses:</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 10.0px; ">Research and development</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">130</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">237</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">1,253</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">1,682</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 10.0px; ">General and administrative</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">4,293</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">4,327</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">21,002</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">18,563</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 10.0px; ">Restructuring</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">-</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">543</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">-</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">1,911</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 20.0px; ">Total operating expenses</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">4,423</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">5,107</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">22,255</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">22,156</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 20.0px; ">&#160;</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 20.0px; ">Loss from operations</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">(4,000</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">)</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">(3,422</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">)</td><td style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">(3,885</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">)</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">(16,857</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">)</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 10.0px; ">&#160;</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="text-align: left ;  vertical-align: middle; ">Other income (expense), net:</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td colspan="3" style="text-align: right ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 20.0px; ">Interest expense</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">(583</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">)</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">(365</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">)</td><td style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">(1,919</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">)</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">(922</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">)</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 20.0px; ">Other income, net</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">262</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">677</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">3,822</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td style="padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">4,338</td><td style="padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="text-align: left ;  vertical-align: middle; ">Loss before income tax</td><td style="border-top: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">$</td><td style="border-top: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">(4,321</td><td style="border-top: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">)</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td style="border-top: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">$</td><td style="border-top: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">(3,110</td><td style="border-top: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">)</td><td style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="border-top: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">$</td><td style="border-top: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">(1,982</td><td style="border-top: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">)</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td style="border-top: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">$</td><td style="border-top: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">(13,441</td><td style="border-top: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">)</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 20.0px; ">Income tax benefit</td><td style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">-</td><td style="border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">98</td><td style="border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">-</td><td style="border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">98</td><td style="border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="text-align: left ;  vertical-align: middle; ">Net loss and comprehensive loss</td><td style="border-bottom: double black 3pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">$</td><td style="border-bottom: double black 3pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">(4,321</td><td style="border-bottom: double black 3pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">)</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td style="border-bottom: double black 3pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">$</td><td style="border-bottom: double black 3pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">(3,012</td><td style="border-bottom: double black 3pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">)</td><td style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="border-bottom: double black 3pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">$</td><td style="border-bottom: double black 3pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">(1,982</td><td style="border-bottom: double black 3pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">)</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td style="border-bottom: double black 3pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">$</td><td style="border-bottom: double black 3pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">(13,343</td><td style="border-bottom: double black 3pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">)</td></tr><tr><td style="text-align: left ;  vertical-align: middle; ">Basic and diluted net loss per share available to common stockholders</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">$</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">(0.49</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">)</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">$</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">(0.35</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">)</td><td class="hugin">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">$</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">(0.23</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">)</td><td style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">$</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">(1.59</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">)</td></tr><tr><td style="text-align: left ;  vertical-align: middle; ">Weighted average shares used in computing basic and diluted net loss per share available to common stochholders</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">8,886</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; ">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">8,430</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td class="hugin">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">8,763</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; ">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ;  vertical-align: middle; ">8,373</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; ">&#160;</td></tr><tr><td class="hugin">&#160;</td><td class="hugin" colspan="3">&#160;</td><td class="hugin">&#160;</td><td class="hugin" colspan="3">&#160;</td><td class="hugin">&#160;</td><td class="hugin" colspan="3">&#160;</td><td class="hugin">&#160;</td><td class="hugin" colspan="3">&#160;</td></tr></table>  <p>  </p>  <p><strong>Investor contact:<br ></strong>Juliane Snowden<br >Oratorium Group, LLC<br >+1 646-438-9754<br >jsnowden@oratoriumgroup.com</p>    <p><strong>Media contact:</strong><br > Kathy Vincent<br > KV Consulting &amp; Management<br > +1 310-403-8951<br > kathy@kathyvincent.com</p>  </p><p ></p></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
